Imdelltra improved overall survival in SCLC patients compared to chemotherapy, regardless of CFIs or prior anti-PD-(L)1 therapy. The DeLLphi-304 trial showed significant OS benefits with Imdelltra, ...

Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival. HealthDay News — For patients with extensive-stage small cell ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...

Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...

Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who receive immune checkpoint inhibition for metastatic lung cancer have ...

Among 854 patients analyzed, durvalumab was initiated at a median of 5.6 weeks after CCRT (IQR, 4.0-8.3 weeks). When not considering the timing of durvalumab, patients who received durvalumab had ...